Risperidone
- PMID: 7524043
Risperidone
Abstract
Risperidone, a benzisoxazole derivative, is a novel antipsychotic agent that has an extremely strong binding affinity for serotonin 5-HT2 receptors, a strong binding affinity for dopamine D2 receptors, and a high affinity for alpha 1- and alpha 2-adrenergic receptors and histamine H1 receptors. Its affinity for serotonin receptors is approximately 200 times greater than that of haloperidol, and its dopamine antagonistic potency is comparable to that of haloperidol. Its major metabolite, 9-hydroxyrisperidone, has similar pharmacologic activity, and thus the parent compound and metabolite form the active antipsychotic moiety. Clinical trials demonstrate that risperidone is an effective antipsychotic agent that improves negative as well as positive symptoms of schizophrenia. At recommended dosages, the frequency of extrapyramidal side effects is no greater than that seen with placebo. The drug appears to be an advance in the treatment of psychoses.
Similar articles
-
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.J Clin Psychiatry. 1994 May;55 Suppl:5-12. J Clin Psychiatry. 1994. PMID: 7520908
-
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.J Pharmacol Exp Ther. 1988 Feb;244(2):685-93. J Pharmacol Exp Ther. 1988. PMID: 2450200
-
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.Arzneimittelforschung. 1994 Mar;44(3):269-77. Arzneimittelforschung. 1994. PMID: 7514873
-
A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.Int Clin Psychopharmacol. 1995 Mar;10(1):19-30. doi: 10.1097/00004850-199503000-00003. Int Clin Psychopharmacol. 1995. PMID: 7542676 Review.
-
Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S46-52. Can J Psychiatry. 1994. PMID: 7533051 Review.
Cited by
-
Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.Neurosci Biobehav Rev. 2009 Jul;33(7):981-1003. doi: 10.1016/j.neubiorev.2009.03.011. Epub 2009 Apr 1. Neurosci Biobehav Rev. 2009. PMID: 19580914 Free PMC article. Review.
-
Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):50-7. doi: 10.1111/j.1365-2125.2004.01817.x. Br J Clin Pharmacol. 2004. PMID: 15496223 Free PMC article. Clinical Trial.
-
Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity.J Nanobiotechnology. 2020 Oct 21;18(1):149. doi: 10.1186/s12951-020-00709-z. J Nanobiotechnology. 2020. PMID: 33087104 Free PMC article.
-
Isolated sinus tachycardia following reinitiation of risperidone in a patient with suspected autonomic hypersensitivity.J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):42-4. doi: 10.4103/0976-500X.149147. J Pharmacol Pharmacother. 2015. PMID: 25709354 Free PMC article.
-
Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.Int J Neuropsychopharmacol. 2011 Nov;14(10):1357-66. doi: 10.1017/S1461145711000514. Epub 2011 Apr 11. Int J Neuropsychopharmacol. 2011. PMID: 21477416 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources